Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 2,784 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 2,784 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $139,200.00. Following the completion of the transaction, the director now owns 295,810 shares in the company, valued at approximately $14,790,500. The trade was a 0.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pro-Dex Price Performance

Shares of PDEX opened at $49.62 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. Pro-Dex, Inc. has a 1-year low of $16.84 and a 1-year high of $59.60. The stock has a market cap of $161.81 million, a PE ratio of 24.69 and a beta of 0.68. The firm has a fifty day moving average price of $39.93 and a 200 day moving average price of $39.61.

Pro-Dex (NASDAQ:PDEX) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, sell-side analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Institutional Investors Weigh In On Pro-Dex

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Pro-Dex during the 4th quarter worth $202,000. Trexquant Investment LP purchased a new stake in shares of Pro-Dex in the fourth quarter valued at about $252,000. Integrated Quantitative Investments LLC acquired a new stake in shares of Pro-Dex during the fourth quarter worth about $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Pro-Dex during the fourth quarter worth about $255,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.